Gene therapy

Gene therapy: A new and innovative facility, new capabilities and new opportunities

Vandenbruaene Nathalie — Tue, 08 Mar 2022 07:33:52 +0000

Gene therapy: A new and innovative facility, new capabilities and new opportunities

Jacques Marbehant, Manufacturing Engineering & Health Safety & Environment

Vandenbruaene … Tue 08/03/2022 - 08:33

We are currently seeing within the industry a fundamental change in how we treat diseases. Therapies are moving from treating symptoms to disease modification. And we expect this trend to follow a trajectory from disease modification to finding a cure for certain diseases in defined patient populations.

Gene therapy is a keep enabler of this trend. But producing the viral vectors that deliver these therapies can be challenging due to currently inefficient manufacturing processes and scarce high-cost third party development and manufacturing capacity.

Advancing our gene therapy journey

I’m excited to tell you about the new gene therapy facility ��ֳ� is building, an innovative and environmentally sustainable facility that marks a significant investment in Belgium. Construction on our campus in Braine-l’Alleud, Wallonia, Belgium, is due to start in the second quarter of 2022, and we expect it to be operational by 2024.

I am so enthusiastic about this significant next step in our gene therapy journey. It will see us enhance both our development and manufacturing capabilities, reinforcing our current gene therapy teams concentrated in Braine and Leuven in Belgium and Boston and Durham in the US. Our process and analytical development capabilities will take a significant leap forward, with the on-site experience giving us an unparalleled understanding of gene therapy products and processes.

What’s more, the efficient clinical manufacturing capability will give us complete ownership of chemistry, manufacturing and controls (CMC) capabilities. It will make us more agile, so we can respond faster to new trends and opportunities, and more scalable to help meet the unmet needs of more patients.

Building gene therapy skills

Alongside building the bricks-and-mortar of our new facility, we will also continue to build on our skills and expertise in gene therapy. And gene therapy is an area that offers a wealth of opportunities.

As well as opening new opportunities to current employees, the new facility will create more than 100 new and highly skilled jobs. That’s why we’re on the lookout for talented, inspired, daring and engaged individuals who, like us, have a passion for improving lives.

So, join us! We have unique opportunities and exciting positions waiting for you!

innovation

Comment:

Posted by Belaïd sekkali, 24 March 2022

Congratulations for the new GMP facility dedicated to GTMP manufacturing for clinical (and may be commercial?) use!

664 Likes

Bringing diverse mindsets together to meet patient needs

eCMSadmin — Mon, 06 Dec 2021 10:30:00 +0000

Bringing diverse mindsets together to meet patient needs

Laetitia Malphettes, Gene Therapy CMC Development Sciences

eCMSadmin Mon 06/12/2021 - 11:30

Over the last few years, the pharmaceutical industry has begun to recognise the importance of fostering a diverse, inclusive, and culturally intelligent environment. Additionally, throughout our industry, there is a unified drive to ensure that people living with diseases are supported to live their best quality of life.

There are many facets to consider to effectively reach these goals. One most notable characteristic is the empathetic nature that companies must pursue to understand patient needs. In order to provide the greatest value for patients, it is vital that our industry recognizes that different patient populations are faced with varying challenges. To become a company that truly appreciates the needs of patients, then we must consider how insights brought through a diverse and inclusive environment can provide the most impact across all aspects of the pharmaceutical value chain.

At ��ֳ�, from research to development and manufacturing, patients are at the heart of everything we do, and we are committed to fostering a supportive, diverse and respectful company culture for all employees, as we believe it helps us to work effectively at the cutting edge of science. Take my gene therapy team. Our composition is made up of a large variety of backgrounds and experiences, and by embracing these diverse talents and experiences, we can maximize the value we create for patients.

��ֳ� is its people – and we are made stronger because of our culture of collaboration and curiosity. We nurture and value diverse perspectives and backgrounds and practice respect and care for each other, for our communities, for our planet and for the people who inspire and define our purpose. We are continually looking for like-minded people to partner with and join our growing team to give us a greater appreciation of each individual reality and create a meaningful difference in the lives of patients.

As we continue to strengthen our gene therapy team, we are looking to attract bright minds who see how science can express our deepest humanity, who push boundaries with purpose and thoughtful intent, who are drawn to discovery and innovation, to create value for people living with severe diseases and want to improve the health and wellbeing of the society in which we live. We value pluralists who bring together purposeful initiatives resulting from true insights, which have their roots in diversity of thought, accountability and a continuous growth mindset.

So, if you are curious, bold, want to make gene therapy happen and like the sound of how our teams tick, then this is the moment to join us. To learn more about working in our gene therapy team visit our recruitment site here.

innovation

Gene therapy research development

915 Likes

��ֳ� strengthens its gene therapy activities

eCMSadmin — Thu, 12 Nov 2020 08:00:00 +0000

��ֳ� strengthens its gene therapy activities

Dhavalkumar Patel, Patient Value Early Solutions

eCMSadmin Thu 12/11/2020 - 09:00

��ֳ�’s ambition for patients relies on our ability to innovate and deliver highly differentiated medicines with unique outcomes. Today’s announcement of the acquisition of Handl Therapeutics BV and our new R&D partnership with Lacerta Therapeutics is great news as it advances our ability to develop novel treatments using state of the art gene therapy techniques.

��ֳ� has a vision to move from symptomatic treatments to disease modification and eventually towards a cure. AAV-mediated gene therapy offers to deliver that potential and drive a fundamental change in how diseases are treated with the ability to remove or add disease-related proteins with a single treatment. A vast array of diseases are amenable to gene therapy and ��ֳ� is embracing this modality to expand its capabilities and ultimately transform the lives of patients with severe diseases.

Handl Therapeutics BV is a Belgium born, transformative gene therapy company with a vision to deploy the power of disease modifying in vivo gene therapy to treat complex neurodegenerative diseases. Operating in a highly collaborative manner, the company has built a strong international network to access global capabilities and expertise. To this end, it combines state of the art technology platforms and scientific advances licenced from KU Leuven (Belgium), Centre for Applied Medical Research (CIMA Universidad de Navarra, Spain), University of Chile (Chile) and King’s College London (UK) to address unmet medical needs. The team will continue to be based in Leuven, Belgium, and will work very closely with ��ֳ�’s international research teams.

The research collaboration with Lacerta Therapeutics will focus on the development of a gene therapy treatment for a central nervous system disorder with a high unmet need. Lacerta will lead research, preclinical activities and the early manufacturing process development, while ��ֳ� will complete IND-enabling studies, manufacturing and clinical development. This new collaboration will allow ��ֳ� to access Lacerta Therapeutics’ expertise in AAV-based CNS targeted gene therapies, fortifying ��ֳ�’s ability to produce effective treatments for neurodegenerative diseases.

These two new strategic investments, along with ��ֳ�’s acquisition of Element Genomics in 2018, support and accelerate our long-term goal to drive a fundamental change in how diseases are treated, by moving from treating symptoms to disease modification and eventually, towards a cure for several severe chronic diseases.

We would like to give a warm welcome to our new colleagues and partners and look forward to an exciting and successful future together.

innovation

Gene therapy research Lacerta Therapeutics Handl Therapeutics

639 Likes

Gene therapy

Gene therapy: A new and innovative facility, new capabilities and new opportunities

Leave a Comment

Bringing diverse mindsets together to meet patient needs

Leave a Comment

��ֳ� strengthens its gene therapy activities

Leave a Comment

Gene therapy

Gene therapy: A new and innovative facility, new capabilities and new opportunities

Leave a Comment

Bringing diverse mindsets together to meet patient needs

Leave a Comment

������ֳ� strengthens its gene therapy activities

Leave a Comment

��ֳ� strengthens its gene therapy activities